RenalGuard Solutions

Executive Summary

RenalGuard Solutions is a U.S.-based medical device company focused on preventing acute kidney injury (AKI) through its proprietary RenalPro™ system. The device, which has received FDA Breakthrough Device designation, autonomously integrates fluid management and therapeutic systems to respond to real-time urine output fluctuations, seamlessly fitting into existing clinical workflows. AKI is a common and serious complication in hospitalized patients, particularly those undergoing cardiac surgery or receiving contrast agents, and is associated with significant morbidity, mortality, and healthcare costs. RenalPro™ aims to fill a critical gap by enabling early, precise intervention to preserve kidney function. Since its founding in 2008, the company has progressed its technology through development and is now approaching commercialization. The FDA Breakthrough Device designation suggests a pathway to expedited review and potential market entry within the next 12-18 months. RenalGuard Solutions targets a large addressable market, given the prevalence of AKI in multiple clinical settings. The company's innovative approach and favorable regulatory designation position it as a compelling player in the cardiovascular and diagnostic device space, though it remains privately held with limited public financial disclosures.

Upcoming Catalysts (preview)

• Q1 2027FDA Clearance or Approval of RenalPro™65% success
• Q3 2026Publication of Pivotal Clinical Trial Results70% success
• Q4 2026Strategic Partnership or Distribution Agreement50% success